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Successful removal of a potentially lethal left atrial thrombus detected
by transesophageal echocardiography following the removal of a left
ventricular assist device inflow cannula
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Received May 10, 2011; accepted October 19, 2011AbstractThe left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device that helps in maintaining the pumping ability of
a failing heart. Thromboembolism poses a significant risk during and after LVAD implantation. It occurs in up to 35% of patients with adverse
sequelae. We present the case of a 75-year-old man who underwent coronary artery bypass graft surgery and LVAD implantation for acute
myocardial ischemia and severe left ventricular dysfunction. However, subsequent transthoracic echocardiographic examination revealed an
LVAD thrombus, and LVAD removal was suggested following the failure of thrombolytic therapy. After the LVAD cannula was removed,
transesophageal echocardiography (TEE) revealed a residual thrombus in the left atrium. Thrombectomy was successfully performed by opening
the left atrium with cardiopulmonary bypass. We believe that TEE monitoring aided the implantation and removal of the LVAD device. In this
case, we found that TEE not only helped in monitoring the ventricular function but also in detecting other problems such as the residual
thrombus. We strongly recommend TEE monitoring during the entire LVAD-removal procedure, particularly for patients who need to undergo
LVAD removal because of thrombosis formation.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: left ventricular assist device; thrombus; transesophageal echocardiography1. Introduction
The left ventricular assist device (LVAD) is a battery-
operated, mechanical pump-type device that is usually used
as a so-called “bridge to transplant” for severe heart failure
patients. However, there are a few problems related to LVAD
usage, of which inflow and outlet cannula obstruction induced
by thrombus formation1 is one of the most severe and
frequently observed. LVAD thrombogenicity2 is mainly due to
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http://dx.doi.org/10.1016/j.jcma.2012.07.010harbored by LVAD Dacron grafts. This complication can lead
to death if the thrombus causes obstruction in the flow between
the concurrent LVAD and a failed heart and then circulatory
collapse follows.
Transesophageal echocardiography (TEE) is the most
commonly used technique for the evaluation of obstructed
LVAD conduits.3 Under TEE observation, pump flow and
performance can be optimized by correct positioning of the
cannula in LVAD recipients. Moreover, TEE may help in
identifying detailed morphologic characteristics of an intra-
cardiac mass lesion, such as a thrombus.4,5
Here, we present the case of a patient with a lethal left atrial
thrombus that was detected by TEE after the removal of the
LVAD cannula. Under TEE monitoring, the LVAD was
successfully removed, and the patient was uneventfully dis-
charged later.hinese Medical Association. All rights reserved.
Fig. 1. Preoperative transthoracic echocardiography revealed a suspected
thrombus encircling the left atrial tubing of the left ventricular assist device
(white arrow).
Fig. 2. Transesophageal echocardiography before the removal of the left
ventricular assist device (LVAD) inflow cannula revealed a thrombus of
diameter 3.52  1.71 cm (arrows) attached to the LVAD inflow cannula in the
left atrium in the mid-esophageal four chamber view.
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A 75-year-old man with a history of hypertension was
admitted to the emergency department because of acute chest
pain and shortness of breath. The patient went into shock when
his blood pressure dropped to 76/48 mmHg. An emergency
electrocardiographic examination revealed sinus rhythm with
ST segment depression and T-wave inversion in leads V3e6.
Serum analysis revealed elevated levels of cardiac enzymes
[creatine kinase (CK), 1245 U/L; MB isoenzyme of CK, 101
U/L; troponin-I, 39 ng/mL]. Emergent coronary angiography
was performed, revealing severe coronary artery disease with
triple vessel disease [LAD-P total occlusion, LCX-P 90%
stenosis, -D 70% stenosis, - OM3 95 % stenosis, RCA-P to -M
segmental stenosis, with collaterals to LAD], apical aneurysm,
acute myocardial infarction, and poor left ventricular (LV)
function. The LV ejection fraction was extremely low, about
13%. Because the patient had severe stenosis of the coronary
artery, stent insertion was considered relatively difficult and
risky. Surgical intervention was suggested, and a cardiovas-
cular surgeon was consulted.
The LV ejection fraction improved to 29% after several
days of medical treatment and intra-aortic pump support.
However, transthoracic echocardiography (TTE) revealed
moderate mitral regurgitation, which resulted from the dilated
mitral annulus with a 10 cm  8-cm LV aneurysm present.
Considering the patient’s poor heart function and that there
were already collaterals from the RCA to the LAD, the
surgeon decided to revascularize only the LCX to shorten the
operation time for to get the most benefit for this patient.
Coronary artery bypass graft (CABG) surgery [gastroepiploic
artery to the first obtuse marginal branch], left ventricular
aneurysmectomy, and mitral valve annuloplasty (28 mm
Edwards IMR ETlogix annuloplasty ring; Edwards, Irvine,
CA, USA) were scheduled. Because of poor LV function and
the high dose of inotropic agents administered during
cardiopulmonary bypass removal, an LVAD (Levitronix Cen-
triMag Blood Pump; Levitronix, Waltham, Mass, USA) was
chosen for circulatory support instead of extracorporeal
membrane oxygenation because of having fewer complica-
tions and better outcome.6 The LVAD was implanted with
inflow from the left atrium and outflow to the ascending aorta;
the flow was maintained at approximately 3.6 L/min.
However, the LVAD flow occasionally dropped to 1.51 L/min,
and TTE revealed a mass over the inflow cannula 3 weeks
after implantation (Fig. 1). The patient received thrombolytic
therapy, but it was ineffective, and therefore the LVAD had to
be removed. Before the procedure, TEE showed an organized
thrombus of diameter 3.52 cm  1.71 cm encircling the LVAD
inflow cannula in the left atrium (Fig. 2). The entire procedure
of LVAD removal under general anesthesia was performed
under real-time TEE monitoring. A lethal thrombus was
detected in the left atrium after the LVAD cannula was
removed (Fig. 3). Cardiopulmonary bypass was performed
immediately, and the thrombus was successfully removed by
opening the left atrial chamber. TEE showed no residual
thrombus in the left atrium(Fig. 4).3. Discussion
LVAD is increasingly used as a bridge to cardiac trans-
plantation,7,8 for destination therapy in patients with end-stage
heart failure and for postcardiotomy cardiogenic shock
occurring in 2% to 6% of all patients undergoing CABG or
valvular surgery.9 However, LVAD usage often poses complex
hematologic challenges, including thromboembolism, which
can lead to death.1 TTE or TEE can be used for thrombus
detection,10 and further management including thrombolytic
therapy or surgical intervention can be carried out.
LVAD recipients often have increased levels of platelet
release and thrombin activity during device implantation.
LVAD Dacron grafts harbor anticoagulation-resistant surface
thrombin activity, which may play an important role in LVAD
thrombogenicity.2 There is evidence of increased thrombin
generation and fibrinolysis in LVAD recipients, despite
Fig. 3. Transesophageal echocardiography after the removal of the left ventricular assist device (LVAD) inflow cannula revealed (A) a retained thrombus after the
removal of the LVAD tube; (B) the tubular thrombus at 80.
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time, and platelet count.1 Thus, thromboembolism is a signif-
icant problem in LVAD implantation; it occurs in up to 35% of
patients with adverse sequelae.11 In an expected short-term-
use LVAD system, continuous intravenous heparin will be
prescribed to keep activated clotting time between 200 andFig. 4. Resected thrombus; (A) the tubular thrombus that was resected; (B) the
cross section of the thrombus.250 seconds. Even though thromboembolism is a significant
risk, and it may be related to the relationship between cannula
size and flow rate, more importantly, it is related to the
concurrent activation of the coagulation and fibrinolytic
systems.12
In our case, we chose the left atrium to be the inflow site of
the LVAD because the operator could instantly establish an
effective circulation system and also because the purpose was
for short-term assistance of LV function. The inflow site and
the native heart function can affect the flow rate; Tevaearai
et al13 concluded that drainage through the left atrium (LA) or
the LV was similar when CVP was set at 8 mmHg, and
increasing CVP to 14 mmHg allowed for better drainage
through the LV cannula. Due to easier collapse of LA and
there is being lower flow through the LVAD inflow cannula
from the LA compared to from the LV, the risk of thrombo-
embolism seems higher in the LVAD recipients with the inflow
from the LA. That may be one reason for our patient receiving
heparin therapy following LVAD implantation; there was still
a thromboembolic event occurring. Some studies report that
thrombolytic therapy has been used to successfully treat
thrombi in LVAD recipients,14,15 while this therapy has been
found to be ineffective in some other studies.16 Similarly, our
patient received heparin for prophylaxis and thrombolytic
therapy following thrombus detection, but the result was
unsatisfactory.
Although TTE revealed the lesion before the operation, the
detailed relationship between the mass lesion, left atrium, and
LVAD inflow cannula was unclear. Instead, TEE can provide
more information on the nature of a lesion.5 In a study by
Srichai,17 TEE showed a higher sensitivity (40%  14%) than
TTE (23%  12%) for thrombus detection in 160 patients with
ischemic heart disease and thrombus formation. Many studies
have proven the greater efficiency of TEE compared to than
TTE in diagnosing cardiovascular diseases4,5,18; TEE allows
identification of detailed morphologic characteristics of
intracardiac mass lesions. In our case, TEE monitoring during
the whole procedure was especially effective because TEE
access is closest to the LA.
Thus, as TEE is a powerful tool for heart evaluation, some
studies have advocated the efficacy of TEE monitoring during
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only in evaluating ventricular function but also for detecting
problems such as a residual thrombus following LVAD dec-
annulation.19 One study with four cases of LVAD malfunc-
tion20 concluded that TEE played a pivotal role in the clinical
management of LVAD failure. TEE can be used not only to
assess the patency and position of the LVAD cannula but also
to examine the source of the thromboembolic material. In our
case, although the LVAD removal procedure did not initially
require cardiopulmonary bypass, we decided to use TEE
monitoring for evaluating the ventricular function and the
nature of the thrombus. This led to the accidental detection of
the thrombus in the left atrium retained after LVAD removal,
which could have led to a lethal complication.
According to the Practice Guidelines for Perioperative
Transesophageal Echocardiography (Anesthesiology 2010;
112:1e1.), TEE monitoring is strongly recommended during
modern open-heart surgery, including LVAD implantation.
However, TEE is not routinely used during the procedures of
cannulation removal of circulatory assist device, such as intra-
aortic balloon, extracorporealmembrane oxygenation device, or
ventricular assist device. These procedures are considered
relatively simple, and some even can be performed at bedside.
There could be a catastrophe if thrombosis formed around the
cannula and residual thrombosis was left in the heart after
cannula removal. Therefore TEE monitoring in these proce-
dures becomes more important. In our case, opening the left
atrium was not in the surgical plan of LVAD removal in the
beginning. If we had not used TEE as amonitoringmodality, the
residual thrombus would not have been detected and lethal
complication might have happened. Furthermore, the inflow
cannula was inserted in the LA, which could be estimated more
precisely by TEE, especially when there were problems such as
decreased inflow rate or mechanical obstruction. Through this
experience, we strongly recommend that TEE should be
routinely used in LVAD removal, especially in cases with
thrombus formation, and also should be considered in the per-
ioperative period when LVAD malfunction happens.
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